Holen Sie sich die Stockscreener-App
9.94
0.65%
-0.08
Schlusskurs vom Vortag:
$10.02
Offen:
$10.15
24-Stunden-Volumen:
253.22K
Relative Volume:
0.81
Marktkapitalisierung:
$566.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.45M
KGV:
-8.3748
EPS:
-1.1869
Netto-Cashflow:
$-52.41M
1W Leistung:
-0.95%
1M Leistung:
-1.14%
6M Leistung:
+65.09%
1J Leistung:
+110.91%
1-Tages-Spanne:
$9.87
$10.35
1-Wochen-Bereich:
$9.69
$10.83
52-Wochen-Spanne:
$2.60
$11.14
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.94 | 570.78M | 0 | -67.45M | -52.41M | -1.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.75 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.28 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.21 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.43 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com South Africa
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Design Therapeutics (NASDAQ:DSGN) Rare Disease Research In Nasdaq Today - Kalkine Media
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Bitget
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
Stock Report: Is Design Therapeutics Inc currently under institutional pressureJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Design Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Antiverse Raises $9.3M Series A to Develop Antibodies for Undruggable Disease Targets and Announces Research Agreement with the Cystic Fibrosis Foundation - Business Wire
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - MarketBeat
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - Defense World
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX) - The Globe and Mail
DSGN.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 - PR Newswire
DSGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials - Business Wire
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00 - Defense World
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ideas Watch: Can Design Therapeutics Inc expand its profit margins2025 Trading Recap & Capital Protection Trade Alerts - baoquankhu1.vn
RSI Check: Is Trinseo PLC a potential multi baggerBond Market & Breakout Confirmation Alerts - baoquankhu1.vn
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
Biotech Design Therapeutics to brief investors at two healthcare events - Stock Titan
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0% - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Design Therapeutics Inc. stock recover after earningsJuly 2025 Sentiment & Fast Exit and Entry Trade Guides - mfd.ru
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Is Design Therapeutics Inc. stock influenced by commodity pricesJuly 2025 Earnings & Verified Chart Pattern Signals - mfd.ru
Trading Action: What is the long term forecast for Design Therapeutics Inc stockDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Retail Surge: Is Design Therapeutics Inc attractive for institutional investorsJuly 2025 Catalysts & Expert-Curated Trade Recommendations - baoquankhu1.vn
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery - Business Wire
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding - AD HOC NEWS
Published on: 2026-02-07 15:17:14 - baoquankhu1.vn
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):